References
- Davidson JA. The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12 Suppl):S3–S4.
- Grant RW, Wexler DJ, Ashburner JM, et al. Characteristics of “complex” patients with type 2 diabetes mellitus according to their primary care physicians. Arch Intern Med. 2012;172(10):821–823.
- International Diabetes Federation. IDF diabetes atlas. 7thed. 2015. cited 2016 Aug 26 Available from: http://www.diabetesatlas.org/
- Eli Lilly and Company. U.S. Food and Drug Administration approves Humalog® 200 units/mL KwikPen®. 2015. [cited 2016 Jul 12]. Available from: https://investor.lilly.com/releaseDetail.cfm?ReleaseID=914999
- Novo Nordisk. Novo Nordisk Receives FDA Approval for Tresiba® (insulin degludec injection) for Adults with Type 1 and Type 2 Diabetes. 2015. [cited 2016 Jul 12]. Available from: http://press.novonordisk-us.com/2015-09-25-Novo-Nordisk-Receives-FDA-Approval-for-Tresiba-insulin-degludec-injection-for-Adults-with-Type-1-and-Type-2-Diabetes
- Sanofi. Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®. 2015. [cited 2016 Jul 12]. Available from: http://www.news.sanofi.us/2015-02-25-Sanofi-Receives-FDA-Approval-of-Once-Daily-Basal-Insulin-Toujeo
- Eli Lilly and Company. U.S. Food and Drug Administration Approves Humulin® R U-500 KwikPen®. 2016. [cited 2016 Jul 12]. Available from: https://investor.lilly.com/releaseDetail.cfm?ReleaseID=951175
- Food and Drug Administration. FDA approves a dedicated syringe to be used with Humulin R U-500 insulin. 2016. [cited 2016 Jul 27]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm510318.htm
- Lamos EM, Younk LM, Davis SN. Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016;12:389–400.
- Meneghini L. New insulin preparations: a primer for the clinician. Cleve Clin J Med. 2016;83(5 Suppl 1):S27–S33.
- Eli Lilly and Company. Humalog Prescribing Information. 2015. [cited 2016 Jul 12]. Available from: http://uspl.lilly.com/humalog/humalog.html#pi
- Eli Lilly and Company. Humalog 200 units/ml KwikPen. 2016. [cited 2017 Feb 1]. Available from: http://www.humalog.com/humalog-u200-hcp.aspx
- Sanofi. Toujeo® Prescribing Information. 2015. [cited 2016 Jul 13]. Available from: http://products.sanofi.us/toujeo/toujeo.pdf
- Food and Drug Administration. Toujeo (insulin glargine injection) U-300, for subcutaneous use. 2015. [cited 2016 Aug 31]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf
- Novo Nordisk. TRESIBA® (insulin degludec injection) Prescribing Information. 2016. [cited 2017 Feb 1]. Available from: http://www.novo-pi.com/tresiba.pdf
- Eli Lilly and Company. Humulin® R U-500 KwikPen®. 2016. [cited 2017 Feb 1]. Available from: http://www.humulin.com/assets/pdf/PP_HM_US_0397_U-500_Patient_Starter_Brochure.pdf
- Eli Lilly and Company. Humulin® R U-500 KwikPen®. 2015. [cited 2017 Feb 1]. Available from: http://pi.lilly.com/us/humulin-r-u500-kwikpen-us-ifu.pdf
- European Medicines Agency. Guideline on the Investigation of Bioequivalence. 2010. [cited 2016 Jul 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
- Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs - general considerations. 2014. [cited 2016 May 27]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf
- Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units. mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL-1. Diabetes Care. 2015;38(4):637–643.
- ClinicalTrials.gov. A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants (NCT02111083). 2016. [cited 2016 May 31]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02111083?sect=X87a0156#outcome2
- De La Peña A, Seger M, Soon D, et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL. Clin Pharmacol Drug Dev. 2016;5(1):69–75.
- Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33(7):515–521.
- Barnosky A, Shah L, Meah F, et al. A primer on concentrated insulins: what an internist should know. Postgrad Med. 2016;128(4):381–390.
- Segal AR, El Sayed N. Are you ready for more insulin concentrations? J Diabetes Sci Technol. 2015;9(2):331–338.
- De La Peña A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496–2501.
- Wang T, Conrad KA, van Brunt K, et al. Attributes influencing insulin pen preference among caregivers and patients with diabetes who require greater than 20 units of mealtime insulin. J Diabetes Sci Technol. 2016;10(4):923–931.
- Hood RC, Arakaki RF, Wysham C, et al. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract. 2015;21(7):782–793.
- CORRECTION. Endocr Pract. 2016:22(7):905. [This is an Erratum for the above reference 28]
- Eli Lilly and Company. HUMULIN R U-500 Prescribing Information. 2016. [cited 2017 Feb 1]. Available from: http://pi.lilly.com/us/humulin-r-u500-pi.pdf
- Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–950.
- Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14(9):859–864.
- Bode BW, Chaykin LB, Sussman AM, et al. Efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (BEGIN: COMPARE). Endocr Pract. 2014;20(8):785–791.
- Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–1507.
- Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–2542.
- Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–864.
- Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464–2471.
- Novo Nordisk. TRESIBA® insulin degludec injection 200 Units/mL. 2016. [cited 2017 Feb 1]. Available from: https://www.tresiba.com/tresiba-flextouch/meet-tresiba-flextouch.html?campaign=000840236&gclid=CJCkr6bX8M0CFcUmhgodrRUCFQ
- Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–394.
- Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762.
- Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235–3243.
- Sanofi. Lantus® Prescribing Information. 2015. [cited 2016 Jul 13]. Available from: http://products.sanofi.us/lantus/lantus.html
- Sanofi. Toujeo® insulin glargine injection 300 Units/mL. 2016. [cited 2017 Feb 1]. Available from: https://www.toujeopro.com/toujeo-solostar-pen
- Sanofi. Lantus® Insulin Glargine Injection 100 Units/ml. 2016. [cited 2016 Aug 30]. Available from: https://www.lantus.com/hcp/dosing-titration/injection-guide
- Klonoff D. Accuracy and injection force of the Gla-300 injection device compared with other commercialized disposable insulin pens. J Diabetes Sci Technol. 2016;10(1):125–130.
- Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71–79.
- Segal AR, Brunner JE, Burch FT, et al. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm. 2010;67(18):1526–1535.
- Reutrakul S, Wroblewski K, Brown RL. Clinical use of U-500 regular insulin: review and meta-analysis. J Diabetes Sci Technol. 2012;6(2):412–420.
- Jones P, Idris I. The use of U-500 regular insulin in the management of patients with obesity and insulin resistance. Diabetes Obes Metab. 2013;15(10):882–887.
- Eli Lilly and Company. HUMULIN R U-500 - insulin human injection, solution, HUMULIN R U-500 KWIKPEN - insulin human injection, solution. 2016. [cited 2016 Jul 13]. Available from: http://uspl.lilly.com/humulinru500/humulinru500.html#ppi
- Garcia-Perez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–194.
- Bohnet J, Schmitz MF, Kamlot SFAU, et al. Dosing accuracy and insulin flow rate characteristics of a new disposable insulin pen, FlexTouch, compared with SoloSTAR. J Diabetes Sci Technol. 2013;7(4):1021–1026.
- Gotzche D, Rasmussen BØ, Pedersen MT, et al. Injection force and dose accuracy of FlexTouch for the delivery of a new basal insulin. Expert Opin Drug Deliv. 2013;12(12):1613–1619.
- Rees TM, Lennartz AH, Ignaut DA. A comparison of glide force characteristics between 2 prefilled insulin lispro pens. J Diabetes Sci Technol. 2015;9(2):316–319.
- Klonoff D, Nayberg I, Erbstein F, et al. Usability of the Gla-300 injection device compared with three other commercialized disposable insulin pens: results of an interview-based survey. J Diabetes Sci Technol. 2015;9(4):936–938.
- Pfutzner A, Forst T, Niemeyer M, et al. Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals. Expert Opin Drug Deliv. 2014;11(9):1381–1389.
- American Association of Clinical Endocrinologists. AACE/ACE comprehensive type 2 diabetes management algorithm. 2017. [cited 2017 Feb 1]. Available from: https://www.aace.com/publications/algorithm
- American Diabetes Association. Standards of medical care in diabetes. 2017. [cited 2017 Feb 1]. Available from: http://professional.diabetes.org/sites/professional.diabetes.org/files/media/dc_40_s1_final.pdf